| 1 |
Segall L, Oprisiu R, Fournier A, et al. Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials [J]. J Nephrol, 2008, 21(3): 374-83.
|
| 2 |
Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta- analysis of randomised controlled trials [J]. Lancet, 2009, 373(9668): 1009-1015.
|
| 3 |
Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH- ESC practice guidelines for the management of arterial hypertension: ESH- ESC task force on the management of arterial hypertension [J]. J Hypertens, 2007, 25(9): 1751-1762.
|
| 4 |
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens, 2013, 31(7): 1281-1357.
|
| 5 |
James PA, Oparil S, Carter BL, et al. 2014 evidence- based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [J]. JAMA, 2014, 311(5): 507-520.
|
| 6 |
中国高血压防治指南修订委员会．中国高血压防治指南2010[J]．中华高血压杂志，2011，19(8): 701-742.
|
| 7 |
Appel L, Wright JT Jr, Greene T. Intensive blood- pressure control in hypertensive chronic kidney disease [J]. N Engl J Med, 2010, 363(10): 918-929.
|
| 8 |
Ruggenenti P, Perna A, Loriga G, et al. Blood- pressure control for reno- protection in patients with non- diabetic chronic renal disease (REIN- 2): multicentre, randomised controlled trial [J]. Lancet, 2005, 365(9463): 939-946.
|
| 9 |
KDIGO Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J]. Kidney Inter Suppl, 2012, 2(5): 337-414.
|
| 10 |
Raymond R. Blood pressure targets in CKD [J]. Adv Chronic Kidney Dis, 2015, 22(2): 96-101.
|
| 11 |
Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in US veterans with chronic kidney disease: a cohort study [J]. Ann Intern Med, 2013, 159(4): 233-242.
|
| 12 |
Poulter NR, Prabhakaran D, Caulfield M. Hypertension [J]. Lancet, 2015, 386(9995): 801-812.
|
| 13 |
Cohen HW, Hailpern SM, Fang J, et al. Sodium intake and mortality in the NHANES II follow- up study [J]. Am J Med, 2006, 119(3): 275.e7-275.e14.
|
| 14 |
O′Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events [J]. N Engl J Med, 2014, 371(7): 612-623.
|
| 15 |
Humalda JK, Navis G. Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease [J]. Curr Opin Nephrol Hypertens, 2014, 23(6): 533-540.
|
| 16 |
Burnier M, Wuerzner G. Chronic kidney disease: Should sodium intake be restricted in patients with CKD [J]? Nat Rev Nephrol, 2014, 10(7): 363-364.
|
| 17 |
Fan Li, Tighiouart H, Levey AS, et al. Urinary sodium excretion and kidney failure in nondiabetic chronic kidney disease [J]. Kidney Int, 2014, 86(3): 582-588.
|
| 18 |
Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial [J]. JAMA, 2002, 288(19): 2421-2431.
|
| 19 |
Tocci G, Volpe M. End- organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function [J]. Drugs, 2011, 71(8): 1003-1017.
|
| 20 |
Vishram JK, Borglykke A, Andreasen AH, et al. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project [J]. Hypertension, 2012, 60(5): 1117-1123.
|
| 21 |
Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta- analysis[J]. Am Heart J, 2008, 155(5): 791-805.
|
| 22 |
Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients [J]. Kidney Int, 2011, 80(9): 978-985.
|
| 23 |
Ryan MJ, Tuttle KR. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury [J]? Curr Opin Nephrol Hypertens, 2008, 17(5): 443-449.
|
| 24 |
Bakris GL, Weir MR. Angiotensin- converting enzyme inhibitor- associated elevations in serum creatinine: is this a cause for concern [J]? Arch Intern Med, 2000, 160(5): 685-693.
|
| 25 |
K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J]. Am J Kidney Dis, 2005, 45(4 Suppl 3): S1-S153.
|
| 26 |
Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure- lowering agents in adults with diabetes and kidney disease: a network meta- analysis[J]. Lancet, 2015, 385(9982): 2047-2056.
|
| 27 |
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta- analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies [J]. BMJ, 2009, 338: b1665.
|
| 28 |
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol [J]. Lancet, 2002, 359(9311): 995-1003.
|
| 29 |
Ptinopoulou AG, Pikilidou M, Lasaridis AN. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review [J]. Hypertens Res, 2013, 36(2): 91-101.
|
| 30 |
Badve SV, Roberts MA, Hawley CM, et al. Effects of beta- adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta- analysis [J]. J Am Coll Cardiol, 2011, 58(11): 1152-1161.
|
| 31 |
Tangri N, Shastri S, Tighiouart H, et al. β- Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study [J]. Am J Kidney Dis, 2011, 58(6): 939-945.
|
| 32 |
Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed- dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a pre- specified secondary analysis of a randomised controlled trial [J]. Lancet, 2010, 375(9721): 1173-1181.
|
| 33 |
Mann JF, Anderson C, Gao P. Dual inhibition of the renin- angiotensin system in high- risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial [J]. J Hypertens, 2013, 31(2): 414-421.
|
| 34 |
Agarwal R, Flynn J, Pogue V, et al. Assessment and management of hypertension in patients on dialysis [J]. J Am Soc Nephrol, 2014, 25(8): 1630-1646.
|
| 35 |
Agarwal R, Satyan S, Alborzi P, et al. Home blood pressure measurements for managing hypertension in hemodialysis patients [J]. Am J Nephrol, 2009, 30(2): 126-134.
|
| 36 |
Lingerfelt K, Hodnicki D. Hypertension management in patients receiving hemodialysis: the benefits of home blood pressure monitoring [J]. Nephrol Nurs J, 2012, 39(1): 31-36.
|
| 37 |
Haskin O, Wong CJ, McCabe L. 44- h ambulatory blood pressure monitoring: revealing the true burden of hypertension in pediatric hemodialysis patients [J]. Pediatr Nephrol, 2015, 30(4): 653-660.
|
| 38 |
Ram CV, Fenves AZ. Management of hypertension in hemodialysis patients [J]. Curr Hypertens Rep, 2009, 11(4): 292-298.
|
| 39 |
Tang X, Hu X, Mei C, et al. Improvement of resistant hypertension by nocturnal hemodialysis in a patient with end- stage kidney disease [J]. Case Rep Nephrol Dial, 2015, 5(1): 60-65.
|
| 40 |
Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality among patients with end- stage renal disease [J]. Kidney Int, 2002, 61(6): 2157-2164.
|
| 41 |
Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two- year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo- controlled trial [J]. J Am Coll Cardiol, 2003, 41(9): 1438-1444.
|
| 42 |
Agarwal R, Sinha AD, Pappas MK, et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial [J]. Nephrol Dial Transplant, 2014, 29(3): 672-681.
|